Glenmark Pharmaceuticals today reported that a blend of antiviral medications Umifenovir and Favipiravir didn’t show any prevalent result in treating Covid ailment patients hospitalized with moderate indications during clinical preliminaries.
this mix study was one more exertion on our part to inspect new treatment alternatives to battle the wellbeing emergency. These most recent discoveries affirm that the expansion of Umifenovir doesn’t show any steady advantage in clinical results. In this manner Favipiravir treatment alongside steady consideration stays an appropriate and compelling decision for mellow to direct Covid-19 disease,” said Monika Tandon, senior VP and head, clinical turn of events, worldwide forte, marked portfolio, Glenmark.
